What is ArrowBiome?
ArrowBiome operates at the intersection of biotechnology and human health, specializing in the precise targeting of bacteria within the human microbiome. Leveraging patented platform technologies, the company addresses critical areas such as body odour, acne, various skin conditions, gut health, and the growing concern of antimicrobial resistance. Their scientific approach aims to enhance health and quality of life by offering science-driven, customized microbiome solutions designed for long-term well-being.
How much funding has ArrowBiome raised?
ArrowBiome has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2024): $1M with participation from Cocoon Capital
Key Investors in ArrowBiome
Cocoon Capital
Cocoon Capital is a Singapore-based venture capital firm that specializes in early-stage investments in Deeptech and Enterprise tech companies across Southeast Asia. With over USD 80 million in assets under management, they focus on pre-seed and seed stages, investing between USD 500K and 1.5M in promising startups. The firm is dedicated to supporting founders with strategic guidance and resources, ensuring that no idea is too early to receive investment. Cocoon Capital aims to partner with innovative entrepreneurs, providing personalized mentoring and leveraging a global network to help them succeed.
What's next for ArrowBiome?
With this major enterprise-level funding, ArrowBiome is poised for significant expansion and further development of its proprietary technologies. The strategic investment signals confidence in the company's mission to pioneer advanced microbiome solutions. Future endeavors will likely focus on scaling operations, advancing clinical research, and broadening the application of their selective bacterial targeting across diverse health sectors, reinforcing their position as a leader in microbiome innovation.
See full ArrowBiome company page
